129 related articles for article (PubMed ID: 9010008)
1. A prospective study of suramin-induced peripheral neuropathy.
Chaudhry V; Eisenberger MA; Sinibaldi VJ; Sheikh K; Griffin JW; Cornblath DR
Brain; 1996 Dec; 119 ( Pt 6)():2039-52. PubMed ID: 9010008
[TBL] [Abstract][Full Text] [Related]
2. Suramin-induced neuropathy in an animal model.
Russell JW; Gill JS; Sorenson EJ; Schultz DA; Windebank AJ
J Neurol Sci; 2001 Nov; 192(1-2):71-80. PubMed ID: 11701155
[TBL] [Abstract][Full Text] [Related]
3. Suramin, an active drug for prostate cancer: interim observations in a phase I trial.
Eisenberger MA; Reyno LM; Jodrell DI; Sinibaldi VJ; Tkaczuk KH; Sridhara R; Zuhowski EG; Lowitt MH; Jacobs SC; Egorin MJ
J Natl Cancer Inst; 1993 Apr; 85(8):611-21. PubMed ID: 8468719
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of neuropathy in patients on suramin treatment.
Soliven B; Dhand UK; Kobayashi K; Arora R; Martin B; Petersen MV; Janisch L; Vogelzang NJ; Vokes EE; Ratain MJ
Muscle Nerve; 1997 Jan; 20(1):83-91. PubMed ID: 8995587
[TBL] [Abstract][Full Text] [Related]
5. Suramin-induced polyneuropathy.
La Rocca RV; Meer J; Gilliatt RW; Stein CA; Cassidy J; Myers CE; Dalakas MC
Neurology; 1990 Jun; 40(6):954-60. PubMed ID: 2161094
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in drug-induced neuropathies.
Peltier AC; Russell JW
Curr Opin Neurol; 2002 Oct; 15(5):633-8. PubMed ID: 12352008
[TBL] [Abstract][Full Text] [Related]
7. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
Bowden CJ; Figg WD; Dawson NA; Sartor O; Bitton RJ; Weinberger MS; Headlee D; Reed E; Myers CE; Cooper MR
Cancer Chemother Pharmacol; 1996; 39(1-2):1-8. PubMed ID: 8995493
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
Kobayashi K; Vokes EE; Vogelzang NJ; Janish L; Soliven B; Ratain MJ
J Clin Oncol; 1995 Sep; 13(9):2196-207. PubMed ID: 7666078
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
Reyno LM; Egorin MJ; Eisenberger MA; Sinibaldi VJ; Zuhowski EG; Sridhara R
J Clin Oncol; 1995 Sep; 13(9):2187-95. PubMed ID: 7666077
[TBL] [Abstract][Full Text] [Related]
10. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
Eisenberger MA; Sinibaldi VJ; Reyno LM; Sridhara R; Jodrell DI; Zuhowski EG; Tkaczuk KH; Lowitt MH; Hemady RK; Jacobs SC
J Clin Oncol; 1995 Sep; 13(9):2174-86. PubMed ID: 7666076
[TBL] [Abstract][Full Text] [Related]
11. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ
J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974
[TBL] [Abstract][Full Text] [Related]
12. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.
Velasco R; Bruna J; Briani C; Argyriou AA; Cavaletti G; Alberti P; Frigeni B; Cacciavillani M; Lonardi S; Cortinovis D; Cazzaniga M; Santos C; Kalofonos HP
J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):392-8. PubMed ID: 23813745
[TBL] [Abstract][Full Text] [Related]
13. Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study.
Rapoport BL; Falkson G; Raats JI; de Wet M; Lotz BP; Potgieter HC
Ann Oncol; 1993 Aug; 4(7):567-73. PubMed ID: 8363988
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
Ryan CW; Vokes EE; Vogelzang NJ; Janisch L; Kobayashi K; Ratain MJ
Cancer Chemother Pharmacol; 2002 Jul; 50(1):1-5. PubMed ID: 12111104
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.
Bitton RJ; Figg WD; Venzon DJ; Dalakas MC; Bowden C; Headlee D; Reed E; Myers CE; Cooper MR
J Clin Oncol; 1995 Sep; 13(9):2223-9. PubMed ID: 7666080
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
[TBL] [Abstract][Full Text] [Related]
17. Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.
Kelly WK; Scher HI; Mazumdar M; Pfister D; Curley T; Leibertz C; Cohen L; Vlamis V; Dnistrian A; Schwartz M
J Clin Oncol; 1995 Sep; 13(9):2214-22. PubMed ID: 7666079
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies.
Argyriou AA; Polychronopoulos P; Iconomou G; Koutras A; Kalofonos HP; Chroni E
J Neurol; 2005 Dec; 252(12):1459-64. PubMed ID: 16284715
[TBL] [Abstract][Full Text] [Related]
19. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
Ahles TA; Herndon JE; Small EJ; Vogelzang NJ; Kornblith AB; Ratain MJ; Stadler W; Palchak D; Marshall ME; Wilding G; Petrylak D; Holland JC;
Cancer; 2004 Nov; 101(10):2202-8. PubMed ID: 15484217
[TBL] [Abstract][Full Text] [Related]
20. Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II study.
Miglietta L; Canobbio L; Granetto C; Vannozzi MO; Esposito M; Boccardo F
J Cancer Res Clin Oncol; 1997; 123(7):407-10. PubMed ID: 9260594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
